AbCellera Biologics Inc. (ABCL) P/S ratio

P/S ratio today
43.9×

AbCellera Biologics Inc. (ABCL) trades at 43.9× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 13.6×. That is 54.5% lower than the 29.9× of fiscal 2024. Figures as of 18 Nov 2026, 02:37 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/S ratio today
43.9×
P/S ratio, fiscal 2025
13.6×
Change on fiscal 2024
−54.5%
Highest on record
45.4×fiscal 2020
Lowest on record
6.6×fiscal 2022
Fiscal years on record
62020–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

AbCellera Biologics Inc. P/S ratio, in more detail

Today's figure is 222.5% above the fiscal 2025 year-end.

Across the 6 fiscal year-ends on record (2020–2025), the highest was 45.4× in fiscal 2020 and the lowest 6.6× in fiscal 2022. Today's P/S ratio is higher than at 83% of the 6 fiscal year-ends on record; their median is 21.8×.

History · 6 fiscal years

P/S ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

AbCellera Biologics Inc. P/S ratio, year by year

AbCellera Biologics Inc. (ABCL) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
Today43.9×—$11.03—
202513.6× 54.5% down$3.42$0.25
202429.9× 31.1% down$2.93$0.10
202343.4× 560.9% up$5.71$0.13
20226.6× 45.8% down$10.13$1.54
202112.1× 73.3% down$14.30$1.18
202045.4×—$40.24$0.89
2019———$0.08

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

More on ABCL

AbCellera Biologics Inc., figure by figure

AbCellera Biologics Inc. (ABCL) overview: price, valuation and scorecard

AbCellera Biologics Inc. P/S ratio: questions and answers

What is AbCellera Biologics Inc.'s P/S ratio?

AbCellera Biologics Inc. (ABCL) trades at 43.9× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 13.6×. That is 54.5% lower than the 29.9× of fiscal 2024.

Is AbCellera Biologics Inc.'s P/S ratio high or low compared with its own history?

Today's P/S ratio is higher than at 83% of the 6 fiscal year-ends on record; their median is 21.8×.

What are the highest and lowest P/S ratio figures on record for AbCellera Biologics Inc.?

Across the 6 fiscal year-ends on record (2020–2025), the highest was 45.4× in fiscal 2020 and the lowest 6.6× in fiscal 2022.

How is AbCellera Biologics Inc.'s P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “AbCellera Biologics Inc. (ABCL) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/ABCL/ps-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.